CVE:VRSVerisante Technology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Verisante Technology Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume256,747 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsHeadlinesOptions ChainSocial Media Verisante Technology Inc., a medical device company, engages in commercializing skin cancer detection systems. The company's products comprise Verisante Aura, which helps in the detection of various forms of skin cancer, including basal cell and squamous cell carcinoma, and melanoma; and Verisante Core for the detection of lung, cervical, gastrointestinal, and colo-rectal cancers. It also owns all the rights to the ClearVu and ClearVu Elite endoscopy systems for the detection of lung cancer. Verisante Technology has a licensing agreement with the BC Cancer Agency for the manufacture, distribution, and sale of products based on patented skin cancer detection technology. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology Inc. in January 2011. Verisante Technology Inc. was founded in 2006 and is based in Richmond, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Verisante Technology. Previous Next 2.6 Community Rank Outperform VotesVerisante Technology has received 61 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVerisante Technology has received 58 “underperform” votes. (Add your “underperform” vote.)Community SentimentVerisante Technology has received 51.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Verisante Technology and other stocks. Vote “Outperform” if you believe VRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVerisante Technology does not currently pay a dividend.Dividend GrowthVerisante Technology does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verisante Technology insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Medical Appliances & Equipment Sub-IndustryN/A SectorMedical Current SymbolCVE:VRS Previous Symbol CUSIPN/A CIKN/A Webwww.verisante.com Phone+1-604-6050507Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableOptionable TSXV:VRS Rates by TradingView Receive VRS News and Ratings via Email Sign-up to receive the latest news and ratings for VRS and its competitors with MarketBeat's FREE daily newsletter. Verisante Technology (CVE:VRS) Frequently Asked Questions Has Verisante Technology been receiving favorable news coverage? Media coverage about VRS stock has trended negative on Thursday, InfoTrie reports. The research firm rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Verisante Technology earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Verisante Technology. Who are some of Verisante Technology's key competitors? Some companies that are related to Verisante Technology include Smith & Nephew (SN), Corindus Vascular Robotics (CVRS), Consort Medical (CSRT), Ekf Diagnostics (EKF), Immunodiagnostic Systems (IDH), Theralase Technologies (TLT), Intelligent Ultrasound Group (MED), LiDCO Group (LID), Deltex Medical Group (DEMG), InspireMD (NSPR), Zecotek Photonics (ZMS), Lucid (LCDX) and MCP Income Opp Trust Ordinary Units FP (MOT). View all competitors. Who are Verisante Technology's key executives? Verisante Technology's management team includes the following people: Mr. Thomas A. Braun BA, J.D., LLM, Chief Exec. Officer, Pres and Director (Age 50)Ms. Anna Trinh B.Comm LLB, Chief Financial Officer, Corp. Counsel and Sec. (Age 44)Mr. Rizah Bahic, Exec. Officer What is Verisante Technology's stock symbol? Verisante Technology trades on the Canadian Venture Exchange (CVE) under the ticker symbol "VRS." How do I buy shares of Verisante Technology? Shares of VRS and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Verisante Technology's official website? The official website for Verisante Technology is www.verisante.com. How can I contact Verisante Technology? Verisante Technology's mailing address is 2309 41st Ave W Suite 306, VANCOUVER, BC V6M 2A3, Canada. The company can be reached via phone at +1-604-6050507. This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
